Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ISHIHARA SANGYO KAISHA, LTD. ( (JP:4028) ) just unveiled an update.
Ishihara Sangyo Kaisha reported a strong fiscal year to March 31, 2026, with net sales up 6.7% to ¥154.9 billion and operating profit surging 82% to ¥19.1 billion, driving profit attributable to owners of the parent up 97.8% to ¥16.6 billion and lifting margins and return on equity. The company strengthened its financial position with higher total assets and equity, increased year-end and interim dividends to a total of ¥120 per share, expanded its consolidation scope with the addition of ISK Biosciences India, but projected a notable profit decline for fiscal 2027 despite relatively stable sales, signaling expectations of margin pressure or higher costs ahead.
Cash flows remained robust as operating cash inflow reached ¥17.3 billion, funding substantial investing outflows while still boosting cash and cash equivalents to ¥29.4 billion. Management also plans to raise total annual dividends further to ¥130 per share in fiscal 2027, even as forecasts point to a 3.2% drop in sales and a more than 45% fall in profit attributable to owners of the parent, a combination that may reassure shareholders in the near term but underscores a more cautious earnings outlook.
More about ISHIHARA SANGYO KAISHA, LTD.
Ishihara Sangyo Kaisha, Ltd. is a Japanese chemical manufacturer listed on the Tokyo Stock Exchange. The company operates under Japanese GAAP and focuses on producing industrial chemicals and related materials, serving domestic and international markets with a diversified portfolio of chemical products.
Average Trading Volume: 352,007
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen131.3B
Learn more about 4028 stock on TipRanks’ Stock Analysis page.